State Board of Administration of Florida Retirement System lowered its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 2.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 287,853 shares of the medical research company’s stock after selling 6,901 shares during the period. State Board of Administration of Florida Retirement System owned approximately 0.14% of Edwards Lifesciences worth $53,178,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of EW. Ledyard National Bank boosted its holdings in Edwards Lifesciences by 0.5% in the second quarter. Ledyard National Bank now owns 9,178 shares of the medical research company’s stock worth $1,696,000 after purchasing an additional 50 shares during the period. Municipal Employees Retirement System of Michigan boosted its holdings in Edwards Lifesciences by 1.8% in the second quarter. Municipal Employees Retirement System of Michigan now owns 2,880 shares of the medical research company’s stock worth $532,000 after purchasing an additional 50 shares during the period. Tarbox Family Office Inc. boosted its holdings in Edwards Lifesciences by 48.7% in the second quarter. Tarbox Family Office Inc. now owns 177 shares of the medical research company’s stock worth $33,000 after purchasing an additional 58 shares during the period. Advisory Services Network LLC boosted its holdings in Edwards Lifesciences by 0.4% in the second quarter. Advisory Services Network LLC now owns 14,932 shares of the medical research company’s stock worth $2,759,000 after purchasing an additional 59 shares during the period. Finally, BB&T Corp boosted its holdings in Edwards Lifesciences by 2.2% in the first quarter. BB&T Corp now owns 2,903 shares of the medical research company’s stock worth $556,000 after purchasing an additional 63 shares during the period. Institutional investors own 81.90% of the company’s stock.

In related news, VP Catherine M. Szyman sold 372 shares of Edwards Lifesciences stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $214.53, for a total transaction of $79,805.16. Following the sale, the vice president now directly owns 18,010 shares in the company, valued at $3,863,685.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 22,850 shares of Edwards Lifesciences stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $184.27, for a total transaction of $4,210,569.50. Following the sale, the chief executive officer now owns 95,770 shares in the company, valued at $17,647,537.90. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 137,951 shares of company stock worth $27,076,240. Company insiders own 1.63% of the company’s stock.

Shares of EW traded down $0.10 during midday trading on Wednesday, hitting $221.91. 244,576 shares of the stock traded hands, compared to its average volume of 1,154,940. Edwards Lifesciences Corp has a 1-year low of $136.44 and a 1-year high of $226.41. The firm has a market capitalization of $46.40 billion, a PE ratio of 47.21, a price-to-earnings-growth ratio of 2.76 and a beta of 0.87. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.48 and a current ratio of 3.38. The business’s 50 day moving average price is $204.84 and its two-hundred day moving average price is $185.93.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the company posted $1.24 earnings per share. The company’s revenue for the quarter was up 15.2% compared to the same quarter last year. As a group, equities research analysts forecast that Edwards Lifesciences Corp will post 5.34 EPS for the current fiscal year.

A number of equities analysts have commented on EW shares. BTIG Research reaffirmed a “hold” rating on shares of Edwards Lifesciences in a report on Thursday, July 25th. Barclays lifted their price objective on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the stock an “underweight” rating in a report on Wednesday, July 24th. Raymond James lifted their price objective on shares of Edwards Lifesciences from $200.00 to $232.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $210.00 to $228.00 and gave the stock an “overweight” rating in a report on Wednesday, July 24th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $204.74.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: What are the reasons investors use put options?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.